Volition Announces Data to Support Use of Nu.Q® NETs in New Indication
Rhea-AI Summary
Volition (NYSE: VNRX) announced a clinical study showing use of its Nu.Q® NETs assay to manage Hidradenitis Suppurativa (HS), a chronic immune-mediated disease affecting ~1% of the global population. The release notes the Nu.Q® NETs assay is CE‑Marked and commercially available across 27 EU member states, 3 EEA countries (Iceland, Liechtenstein, Norway) and the U.K.
The company cites a $3.8 billion Total Addressable Market (Data on File: Volition TAM Model) and says the test may help classify HS severity, guide treatment decisions and act as a surrogate marker for response, specifically noting circulating H3.1‑nucleosomes as a candidate blood marker. The paper is noted as available on medRXIV and includes prior related publications.
Positive
- Assay is CE‑Marked and commercially available in 27 EU states, 3 EEA countries and the U.K.
- Study indicates Nu.Q® NETs can classify HS severity and surrogate treatment response
- Company cites a $3.8 billion Total Addressable Market for NETosis indications
Negative
- Key paper noted as posted on medRXIV, a preprint repository rather than a final peer‑reviewed journal publication
- TAM figure ($3.8B) is from the company's Data on File: Volition TAM Model, not an independent estimate
News Market Reaction
On the day this news was published, VNRX declined 0.19%, reflecting a mild negative market reaction. Argus tracked a peak move of +5.6% during that session. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $62K from the company's valuation, bringing the market cap to $33M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
VNRX is down 5.32% while peers show mixed moves: ICCM slightly positive and several (LUNG, TELA, APYX, CTSO) down around 3–4%, suggesting stock-specific pressure rather than a uniform sector move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 20 | Vet test expansion | Positive | +8.4% | Expanded Nu.Q® Vet Cancer test access via U.S. and Asia lab partners. |
| Jan 16 | Conference sponsorship | Positive | +0.6% | Sponsored VMX symposium to promote Nu.Q® Vet Cancer test adoption. |
| Jan 08 | Convertible funding deal | Positive | +24.2% | Secured <b>$2.0M</b> gross via secured convertible note and warrant package. |
| Jan 08 | Feline trial data | Positive | +24.2% | Reported feline assay with 100% specificity and >80% lymphoma detection. |
| Dec 17 | Business review update | Positive | +10.3% | Outlined 2025 commercial milestones and first Nu.Q NETs revenues and deals. |
Recent company news has typically been followed by positive price reactions, so today’s negative move against seemingly constructive clinical data is atypical.
Over the past months, Volition has highlighted commercial expansion and clinical validation across its Nu.Q® platform. Key milestones include new Nu.Q® Vet Cancer distribution in the U.S. and Asia, a sponsored veterinary oncology symposium, and breakthrough feline assay data with strong specificity and detection rates. Funding was secured via a $2.0 million convertible note and warrant deal, while a 2025 Business Review detailed first Nu.Q NETs revenues and major partnerships. Against this backdrop, the new Nu.Q® NETs data in hidradenitis suppurativa extends clinical utility into a chronic human indication.
Regulatory & Risk Context
The company has an effective S-3 shelf registration filed on 2025-07-03, with at least 4 recorded usages via 424B5 prospectus supplements through 2025-10-14.
Market Pulse Summary
This announcement expands Nu.Q® NETs into hidradenitis suppurativa, a chronic immune‑mediated disease affecting about 1% of the global population, supported by a cohort study of plasma H3.1‑nucleosomes. It reinforces a growing body of published evidence and targets a stated $3.8 billion Total Addressable Market for NETosis‑associated conditions. In context of prior Nu.Q® Vet and NETs milestones, investors may watch for further clinical validation, commercialization updates, and any capital-structure developments disclosed in regulatory filings.
Key Terms
netosis medical
biologicals medical
precision medicine medical
biomarker medical
cohort study medical
total addressable market financial
AI-generated analysis. Not financial advice.
Nu.Q® Biomarker Paper Available on MedRXIV
The Nu.Q® NETs assay is CE-Marked to detect diseases associated with NETosis and is therefore approved and commercially available for clinical use in 27 European Union (EU) member states, the three European Economic Area (EEA) countries (
Mr. Remi Rabeuf, VP Corporate Alliances and Strategic Partnership, Volition added:
"We are excited to report the findings of this clinical study, which focused on a chronic disease, HS. It paves the way to improve a patient's management through a personalized medicine approach.
"This study, together with previously published evidence[2-5], demonstrates that Nu.Q® NETs should enable clinicians and researchers to anticipate disease, guide treatment decisions, and monitor patients over time, across both acute and chronic conditions.
"Nu.Q® NETs is a simple, low-cost, accessible test to detect diseases associated with NETosis. The market opportunity for such indications is significant, with a Total Addressable Market of
Professor Evangelos J. Giamarellos-Bourboulis, M.D., PhD, at the 4th Department of Internal Medicine, ATTIKON University General Hospital,
"Hidradenitis suppurativa is a complex immune-mediated disorder, with multiple proinflammatory cytokines contributing to its pathogenesis. The clinical presentation may also vary from person to person, making it challenging to manage.
"Since the advent of biologicals in the treatment of HS, there has been growing evidence that treatment response varies greatly so that some patients may experience substantial improvement, others no benefit at all and some may even worsen.
"Those considerations call for a precision medicine approach, and the need for a biomarker that would reflect HS disease activity and surrogate response to treatment.
"The findings described in the manuscript demonstrate that for the first time an easy-to-measure blood test, Nu.Q® NETs, can be used to classify patients and to surrogate treatment.
"In addition, given the various biologic therapies being investigated, circulating H3.1-nucleosomes is a new blood marker in HS that may be used to initiate trials where treatment guidance for both initiation and early cessation of treatment will be studied."
The paper can be found in link below:
Plasma H3.1-Nucleosomes to Classify Severity and Surrogate Response to Treatment in Hidradenitis Suppurativa : A Cohort Study
1. Bouazzi D, Nielsen SM, Hagan PG, et al. JAMA Dermatol. 2025. https://doi.org/10.1001/jamadermatol.2025.2373
2. Morimont et al. Biomolecules, 2022. https://doi.org/10.3390/biom12081038
3. Rahimi et al, Ann Intensive Care 2023. https://doi.org/10.1186/s13613-023-01204-y
4. Daan F.L. Filippini et al. Critical Care, 2025. https://doi.org/10.1186/s13054-025-05415-6
5. Neumann et al, MedRXIV
6. Data on File: Volition TAM Model.
About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a lifelong, recurring condition that is often difficult to manage. The exact cause of HS is unknown however it is beyond any doubt a chronic neutrophilic disease.
HS is a painful skin condition that causes skin abscesses and scarring on the skin. It is thought to affect about 1 in 100 people.
It is important to recognise and diagnose the condition, including flare-ups, to prevent it getting worse. although the symptoms may improve or eventually stop with treatment.
The condition can have a significant impact on a person's everyday life. Having to regularly change dressings and constantly live with the pain and discomfort of the symptoms can affect a patient's quality of life and lead to depression.
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help detect and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early detection and monitoring have the potential not only to prolong the life of patients, but also to improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries: Louise Batchelor, Volition, mediarelations@volition.com +44 (0)7557 774620
Safe Harbor Statement
Statements in this press release or associated video or link may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, Volition's expectations regarding future publications, Volition's success in securing licensing and/or distribution agreements with third parties for its products, and Volition's expectations regarding the terms of such agreements. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™, Capture-Seq™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release or associated video or link are the property of their respective owners. Additionally, unless otherwise specified, all references to "$" refer to the legal currency of
View original content:https://www.prnewswire.com/news-releases/volition-announces-data-to-support-use-of-nuq-nets-in-new-indication-302671220.html
SOURCE VolitionRx Limited
FAQ
What did Volition (VNRX) announce about Nu.Q® NETs on January 27, 2026?
Where is the Nu.Q® NETs assay approved and commercially available for clinical use?
What market size did Volition (VNRX) cite for NETosis-related indications?
What biomarker did the study identify for Hidradenitis Suppurativa (HS)?
Does the announcement indicate the Nu.Q® NETs study is peer‑reviewed?
